Print article DETROIT A cargo pilot who regularly needed health checkups to keep his license contacted a University of Michigan doctor in 2000. He said he soon learned there was nothing routine about a visit with Robert Anderson. He said Anderson told him to undress, put on a medical gown and get on a table, instead of simply checking the man’s vision, hearing and heart. He said the doctor touched his genitals and gave him a prostate exam. “I was only 33; I probably didn’t need a prostate exam but I was naive,” the Ann Arbor-area man, now 53, told The Associated Press. “He examined my whole body like a dermatologist might. It was very creepy. It was too much. I didn’t go back. . You’re not touching me again.”
Nigeria: Savannah Energy announces new gas sales agreement with Mulak Energy
05 Feb 2021
Savannah Energy, the African-focused British independent energy company sustainably developing high quality, high potential energy projects in Nigeria and Niger, has announced that its Accugas subsidiary has entered into a new gas sales agreement ( GSA ) with
Mulak Energy.
The GSA is initially for a seven-year term. It envisages the supply of gas produced by Savannah s majority-owned Uquo field for an initial two-year period on an interruptible basis (the Interruptible Gas Delivery Period ) and the subsequent five years on a firm contract basis (the Firm Delivery Period ). During the Interruptible Gas Delivery Period, Mulak is able to nominate a maximum daily quantity of up to 2.5 MMscfpd. Volumes in the Firm Delivery Period will be agreed by the parties before the end of the Interruptible Gas Delivery Period. The GSA is priced to reflect Mulak s status as an industrial customer; Accugas
Russia: Rosneft signs agreement on investment incentives for Priobskoye field
08 Feb 2021
Ministry of Finance of Russia and the
Ministry of Natural Resources and the Environment of Russia have signed an agreement on investment incentives for oil production at the
Priobskoye field in the form of an annual mineral extraction tax (MET) deduction of up to 46 billion roubles.
Subject to the agreement, the MET deduction is provided when the monthly average Urals price exceeds the threshold stipulated in the fiscal rule. The agreement has been signed for ten years.
The agreement is mandatory for all parties involved and provides for transparent and easily governed incentive schemes ensuring accelerated field development. The agreement enables Rosneft to expand the drilling footage at the Priobskoye field and increase tax revenues for the national budget.
| 04 February 2021
Following sanctions on the channel in 2020 for failing to preserve due impartiality and a breach of fairness and privacy rules, UK broadcast regulator Ofcom has withdrawn the licence for China Global Television Network (CGTN) to broadcast in the UK.
In the UK, broadcasting laws state that broadcast licensees must have control over the licensed service – including editorial oversight over the programmes they show. In addition, under these laws, licence holders cannot be controlled by political bodies. Ofcom says that after an investigation of the activities of the international English-language satellite news channel, it concluded that CGTN’s licence is wrongfully held by Star China Media Limited which did not meet the legal requirement of having control over the licensed service, and so was not a lawful broadcast licensee.
Hits: 1464
Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis
• Imcyse and Pfizer to collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis
• Pfizer to lead clinical development and commercialization activities
• Imcyse to receive upfront payment in cash and through the purchase of equity in addition to milestone up to $180 million and tiered royalty payments
LIEGE, Belgium I February 03, 2021 I Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced that it has entered into a research collaboration and license agreement with Pfi